Annexin Pharmaceuticals AB

Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.

ANNX | ST

Overview

Corporate Details

ISIN(s):: SE0009664154
LEI:: 5493000JP703HGPJEX27
Country:: Sweden
Address:: KAMMAKARGATAN 48, 111 60 Stockholm
Website:: https://annexinpharma.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Annexin Pharmaceuticals AB is a clinical-stage biotechnology company focused on the therapeutic protein Annexin A5. The company's lead drug candidate, ANXV, is a recombinant human Annexin A5 that targets phosphatidylserine (PS), a lipid exposed on the surface of stressed or damaged cells. By binding to PS, ANXV acts as a cell protector and immunomodulator, counteracting tissue injury and regulating immune responses. The company's primary focus is on developing ANXV for indications with significant unmet medical needs, including Retinal Vein Occlusion (RVO), for which it is currently in Phase 2 clinical trials, and oncology. ANXV has potential as a first-in-class treatment across a broad range of vascular, inflammatory, and cancerous diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Annexin Pharmaceuticals AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Annexin Pharmaceuticals AB

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Annexin Pharmaceuticals AB via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
KANABO GROUP PLC Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.	United Kingdom	KNB
Kancera Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.	Sweden	KAN
KANGSTEM BIOTECH CO., LTD. Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.	South Korea	217730
Karo Pharma AB Develops and sells everyday healthcare products, focusing on OTC and skin health in Europe.	Sweden	KARO
KBIO COMPANY Inc. Using a plant-based platform to rapidly develop biologics for public health.	South Korea	038530
Keeps Biopharma Inc. Develops cancer therapies and obesity drugs; manufactures industrial and cleanroom products.	South Korea	256940
Kidswell Bio Corporation Biopharma R&D of biosimilars, biologics, and cell therapies, with a pediatric focus.	Japan	4584
Kinarus Therapeutics Holding AG A specialty pharma firm developing and selling medicines for rare and specialty diseases.	Switzerland	KNRS
KISSEI PHARMACEUTICAL CO.,LTD. Develops innovative drugs for urology, renal diseases, and rare or intractable diseases.	Japan	4547
Klaria Pharma Holding AB Develops oral films for non-invasive drug delivery as an alternative to injections and sprays.	Sweden	KLAR